A Study to Evaluate the Safety, Tolerability, Pharmacokinetics & Drug

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04710615` - Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults	N/A
Completed	`NCT03581994` - DDI Effectiveness and Clinical Awareness	N/A
Recruiting	`NCT03370523` - Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients

See also

Status

Clinical Trial

Phase

Recruiting

NCT04710615 - Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults

N/A

Completed

NCT03581994 - DDI Effectiveness and Clinical Awareness

N/A

Recruiting

NCT03370523 - Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03411122
Study type	Interventional
Source	Sumitomo Pharma America, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	June 30, 2017
Completion date	January 23, 2018

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms